Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Oncology Clinical Trials Market Poised To Hit $20.4 Billion By 2030 With A 6.3% CAGR
The oncology clinical trials market has experienced significant expansion in recent years. This market is projected to reach $15.98 billion in 2026 from $14.99 billion in 2025, progressing at a compound annual growth rate (CAGR) of 6.6%. Historically, the growth can be attributed to factors such as limited therapeutic alternatives for cancer patients, a global rise in cancer incidence, increasing investments in pharmaceutical and biotech research and development, an expanding number of academic clinical research facilities, and enhanced recognition of the crucial role of clinical trials.
The oncology clinical trials market is anticipated to experience robust expansion in the upcoming years. Its value is projected to reach $20.4 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.3%. This growth during the forecast period is attributable to the advancement of personalized oncology treatments, the expansion of multicenter and global trials, the uptake of digital patient monitoring tools, the incorporation of AI and big data into trial design, and an increase in government and private sector funding for oncology research. Significant trends anticipated for the forecast period include the widening scope of immunotherapy and targeted therapy clinical trials, a heightened focus on multicenter and randomized controlled trials, greater investment in post-marketing surveillance and long-term safety studies, the rising adoption of cell and gene therapy trials, and the integration of biomarker and pharmacogenomics studies within oncology research.
Get A Free Sample Report With In-Depth Market Insights:
Oncology Clinical Trials Market Growth Backed By Core Demand Fundamentals
A rising occurrence of cancer is projected to fuel the expansion of the oncology clinical trials market in the future. Cancer incidence is defined as the count of new cancer diagnoses within a given population over a set timeframe. This increase in cancer cases largely stems from detrimental lifestyle choices such as inadequate nutrition, lack of physical activity, tobacco use, and excessive alcohol consumption, all of which heighten the likelihood of developing diverse cancers. Oncology clinical trials contribute to the advancement of cancer treatment by assessing novel therapies and interventions, thereby enhancing patient results through research grounded in evidence. These trials expedite medical innovation by rigorous testing of safety and effectiveness, thus fostering progress across cancer prevention, diagnosis, and patient care. For example, data from October 2025, provided by the UK government health agency, National Health Service (NHS), indicated 354,820 new cancer diagnoses in 2023, averaging 972 daily. This figure represents an increase of 8,605 cases compared to 2022. Consequently, the growing frequency of cancer incidence is a key factor propelling the expansion of oncology clinical trials.
Oncology Clinical Trials Market Segment Performance And Emerging Opportunities
The oncology clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Expanded Access
3) By Therapeutic Modality: Immunotherapy, Targeted Therapy, Chemotherapy, Cell And Gene Therapy, Other Therapeutic Modalities
4) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Other Indications
5) By Sponsor Type: Pharmaceutical And Biotech Companies, Academic And Research Institutes, Government Organizations, Other Sponsor Types
Subsegments:
1) By Phase I: Safety And Dosage Studies, Pharmacokinetics And Pharmacodynamics Studies, Biomarker Identification Studies
2) By Phase II: Efficacy And Side Effects Studies, Dose-Response Relationship Studies, Therapeutic Effectiveness Studies
3) By Phase III: Large-Scale Efficacy Studies, Comparative Effectiveness Studies, Multicenter Randomized Controlled Trials
4) By Phase IV: Post Marketing Surveillance Studies, Long-Term Safety Studies, Quality Of Life Studies
Oncology Clinical Trials Market Growth Trends Reshaping The Competitive Landscape
Major companies within the oncology clinical trials market are concentrating on developing technologically advanced solutions, such as sophisticated bioinformatics platforms, to enhance data analysis, accelerate patient recruitment, and optimize trial outcomes. Advanced bioinformatics platforms are complex software systems that leverage computational tools and algorithms to collect, analyze, and interpret intricate biological and clinical data for research and healthcare applications. For instance, in September 2023, Deep 6 AI, a US-based healthcare technology company, launched an AI-powered genomics module aimed at speeding up enrollment in precision medicine and oncology clinical trials. The module utilizes artificial intelligence and natural language processing to extract both structured and unstructured genomics data from electronic medical records, enabling real-time identification and accurate matching of patients with specific genetic markers. It provides researchers with the capacity to search millions of records for more than 19,000 genes and 30,000 mutation names, significantly accelerating patient recruitment and improving the efficiency of clinical trial design.
Oncology Clinical Trials Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the oncology clinical trials market are Pfizer Inc., Johnson & Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Genentech Inc., BeiGene Ltd., Seagen Inc.
View The Full Oncology Clinical Trials Market Report:
Oncology Clinical Trials Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the oncology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
